Dùng Wellbutrin XL Trị Ưu Trầm Về Mùa Đông

Đây là lần đầu tiên, FDA cho dùng thuốc trị ưu trầm thay đổi theo mùa, nhiều nhất về mùa Đông. Những công phạt của Wellbutrin XL như cơ thể kích thích, buồn bã, khó ngủ. Thử nghiệm cho thấy thuốc tương đối an toàn trị bệnh ưu trầm thay đổi theo mùa. (Xin đọc phần cuối: Ưu Trầm Trong Mùa Ðông, Trần Mạnh Ngô, ., .) FDA Approves the First Drug for Seasonal Depression The Food and Drug Administration (FDA) today approved Wellbutrin XL for prevention of major depressive episodes in patients with a history of seasonal affective. | Dùng Wellbutrin XL Trị Ưu Trầm về Mùa Đông Đây là lần đầu tiên FDA cho dùng thuốc trị ưu trầm thay đổi theo mùa nhiều nhất về mùa Đông. Những công phạt của Wellbutrin XL như cơ thể kích thích buồn bã khó ngủ. Thử nghiệm cho thấy thuốc tương đối an toàn trị bệnh ưu trầm thay đổi theo mùa. Xin đọc phần cuối Ưu Trầm Trong Mùa Đông Trần Mạnh Ngô . . FDA Approves the First Drug for Seasonal Depression The Food and Drug Administration FDA today approved Wellbutrin XL for prevention of major depressive episodes in patients with a history of seasonal affective disorder SAD . This is the first drug approved for SAD. Wellbutrin XL bupropion HCL extended release tablets previously was approved for treatment of major depressive disorder. Seasonal affective disorder can significantly impair the quality of life of patients with this condition said Dr. Steven Galson Director for FDA s Center of Drugs and Research. Today s approval can help patients with this condition to avoid the depressive symptoms and impaired functioning that typically affect them in the fall and winter. The effectiveness of Wellbutrin XL for the prevention of SAD episodes was established in 3 double-blind placebo-controlled trials in adults with a history of major depressive disorder in autumn and winter. Treatment was initiated prior to the onset of symptoms in the autumn September to November and was discontinued following a two-week taper that began the first week of spring fourth week of March . In these trials the percentage of patients who were depression-free at the end of treatment was significantly higher for those on Wellbutrin XL than for those on placebo for all 3 studies combined the overall rate of patients depression-free at the end of treatment was 84 percent for those on Wellbutrin XL compared to 72 percent for those on placebo. Wellbutrin XL s labeling includes a black box warning concerning the increased risk of suicidal thoughts and behavior in pediatric patients treated with .